Bridgeway Capital Management LLC lifted its stake in Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 62.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 224,100 shares of the company's stock after acquiring an additional 85,800 shares during the period. Bridgeway Capital Management LLC owned 0.73% of Sagimet Biosciences worth $1,008,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also made changes to their positions in the company. Wells Fargo & Company MN bought a new stake in shares of Sagimet Biosciences in the 4th quarter worth approximately $31,000. Jacksonville Wealth Management LLC bought a new position in shares of Sagimet Biosciences in the fourth quarter valued at $45,000. Summit Financial Wealth Advisors LLC bought a new position in shares of Sagimet Biosciences in the fourth quarter valued at $61,000. American Century Companies Inc. bought a new position in shares of Sagimet Biosciences in the fourth quarter valued at $90,000. Finally, Stoneridge Investment Partners LLC boosted its stake in shares of Sagimet Biosciences by 22.2% during the 4th quarter. Stoneridge Investment Partners LLC now owns 20,836 shares of the company's stock worth $94,000 after acquiring an additional 3,780 shares in the last quarter. 87.86% of the stock is currently owned by institutional investors.
Sagimet Biosciences Trading Down 3.9%
NASDAQ SGMT traded down $0.13 during trading on Tuesday, reaching $3.18. 504,189 shares of the company's stock were exchanged, compared to its average volume of 859,845. Sagimet Biosciences Inc. has a fifty-two week low of $1.73 and a fifty-two week high of $7.38. The company's fifty day simple moving average is $3.08 and its 200-day simple moving average is $4.20. The firm has a market capitalization of $97.55 million, a PE ratio of -2.22 and a beta of 2.32.
Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.23. Equities analysts forecast that Sagimet Biosciences Inc. will post -1.6 EPS for the current fiscal year.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a "buy" rating and set a $32.00 target price on shares of Sagimet Biosciences in a research report on Tuesday, March 11th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $22.40.
View Our Latest Stock Report on Sagimet Biosciences
Sagimet Biosciences Profile
(
Free Report)
Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.
Read More
Before you consider Sagimet Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sagimet Biosciences wasn't on the list.
While Sagimet Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
